Market News

Artivion (NYSE:AORT) Slides on Trial Failure, Maintains 2022 Guidance

Artivion (NYSE:AORT) shares are sliding in the pre-market session today after stopping a trial evaluating Apixaban for patients that have been treated with mechanical aortic valves.

The PROACT Xa trial was designed to study if patients with On-X mechanical aortic valves could be maintained on Apixaban instead of warfarin.

The independent data and safety monitoring board of the trial determined that, “Blood clots, resulting in a stroke, occurred more frequently in patients receiving Apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk.”

Despite the setback, the company has reiterated its guidance of double-digit revenue growth in 2022.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More